Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway

• Published in: Biomedicines 2022-08, Vol.10 (9), p.2100
• Main Authors: Kim, Hanbyeol, Park, Jeongbae, Kim, Jeong-Mok
• Format: Article
• Language: English
• Subjects: Autophagy; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Drug development; Drug resistance; Enzymatic activity; Enzymes; Growth factors; Immunotherapy; Kinases; Leukemia; Metastasis; Molecular modelling; Monoclonal antibodies; Mutation; N-degron; PROTAC; Proteasomes; Proteins; Proteolysis; Radiation therapy; Review; Targeted cancer therapy; Toxicity; Ubiquitin
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10092100

Extensive progress in understanding the molecular mechanisms of cancer growth and proliferation has led to the remarkable development of drugs that target cancer-driving molecules. Most target molecules are proteins such as kinases and kinase-associated receptors, which have enzymatic activities needed for the signaling cascades of cells. The small molecule inhibitors for these target molecules greatly improved therapeutic efficacy and lowered the systemic toxicity in cancer therapies. However, long-term and high-dosage treatment of small inhibitors for cancer has produced other obstacles, such as resistance to inhibitors. Among recent approaches to overcoming drug resistance to cancers, targeted protein degradation (TPD) such as proteolysis-targeting chimera (PROTAC) technology adopts a distinct mechanism of action by which a target protein is destroyed through the cellular proteolytic system, such as the ubiquitin-proteasome system or autophagy. Here, we review the currently developed PROTACs as the representative TPD molecules for cancer therapy and the N-degrons of the N-degron pathways as the potential TPD ligands.